113 related articles for article (PubMed ID: 25898974)
1. Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis.
Bustany S; Cahu J; Descamps G; Pellat-Deceunynck C; Sola B
J Hematol Oncol; 2015 Apr; 8():40. PubMed ID: 25898974
[TBL] [Abstract][Full Text] [Related]
2. The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma.
Heimberger T; Andrulis M; Riedel S; Stühmer T; Schraud H; Beilhack A; Bumm T; Bogen B; Einsele H; Bargou RC; Chatterjee M
Br J Haematol; 2013 Feb; 160(4):465-76. PubMed ID: 23252346
[TBL] [Abstract][Full Text] [Related]
3. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma.
Davenport EL; Zeisig A; Aronson LI; Moore HE; Hockley S; Gonzalez D; Smith EM; Powers MV; Sharp SY; Workman P; Morgan GJ; Davies FE
Leukemia; 2010 Oct; 24(10):1804-7. PubMed ID: 20703255
[No Abstract] [Full Text] [Related]
4. Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation.
Shah SP; Nooka AK; Jaye DL; Bahlis NJ; Lonial S; Boise LH
Oncotarget; 2016 Sep; 7(37):59727-59741. PubMed ID: 27487129
[TBL] [Abstract][Full Text] [Related]
5. Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer.
Rossi A; Ciafrè S; Balsamo M; Pierimarchi P; Santoro MG
Cancer Res; 2006 Aug; 66(15):7678-85. PubMed ID: 16885369
[TBL] [Abstract][Full Text] [Related]
6. Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment.
Fristedt Duvefelt C; Lub S; Agarwal P; Arngården L; Hammarberg A; Maes K; Van Valckenborgh E; Vanderkerken K; Jernberg Wiklund H
Oncotarget; 2015 Aug; 6(24):20621-35. PubMed ID: 26036313
[TBL] [Abstract][Full Text] [Related]
7. Fisetin, a dietary flavonoid, induces apoptosis of cancer cells by inhibiting HSF1 activity through blocking its binding to the hsp70 promoter.
Kim JA; Lee S; Kim DE; Kim M; Kwon BM; Han DC
Carcinogenesis; 2015 Jun; 36(6):696-706. PubMed ID: 25840992
[TBL] [Abstract][Full Text] [Related]
8. 2,4-Bis(4-hydroxybenzyl)phenol inhibits heat shock transcription factor 1 and sensitizes lung cancer cells to conventional anticancer modalities.
Yoon T; Kang GY; Han AR; Seo EK; Lee YS
J Nat Prod; 2014 May; 77(5):1123-9. PubMed ID: 24746225
[TBL] [Abstract][Full Text] [Related]
9. Ugi Reaction-Derived α-Acyl Aminocarboxamides Bind to Phosphatidylinositol 3-Kinase-Related Kinases, Inhibit HSF1-Dependent Heat Shock Response, and Induce Apoptosis in Multiple Myeloma Cells.
Bach M; Lehmann A; Brünnert D; Vanselow JT; Hartung A; Bargou RC; Holzgrabe U; Schlosser A; Chatterjee M
J Med Chem; 2017 May; 60(10):4147-4160. PubMed ID: 28453931
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of heat shock protein response enhances PS-341-mediated glioma cell death.
Liu Y; Zheng T; Zhao S; Liu H; Han D; Zhen Y; Xu D; Wang Y; Yang H; Zhang G; Wang C; Wu J; Ye Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S421-9. PubMed ID: 21732139
[TBL] [Abstract][Full Text] [Related]
11. Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800.
Stühmer T; Chatterjee M; Grella E; Seggewiss R; Langer C; Müller S; Schoepfer J; Garcia-Echeverria C; Quadt C; Jensen MR; Einsele H; Bargou RC
Br J Haematol; 2009 Nov; 147(3):319-27. PubMed ID: 19686236
[TBL] [Abstract][Full Text] [Related]
12. Sensitizing tumor cells to radiation by targeting the heat shock response.
Schilling D; Kühnel A; Konrad S; Tetzlaff F; Bayer C; Yaglom J; Multhoff G
Cancer Lett; 2015 May; 360(2):294-301. PubMed ID: 25721082
[TBL] [Abstract][Full Text] [Related]
13. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M
J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of glucose transporter 1 induces apoptosis and sensitizes multiple myeloma cells to conventional chemotherapeutic agents.
Matsumoto T; Jimi S; Migita K; Takamatsu Y; Hara S
Leuk Res; 2016 Feb; 41():103-10. PubMed ID: 26790725
[TBL] [Abstract][Full Text] [Related]
15. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
Monaghan KA; Khong T; Burns CJ; Spencer A
Leukemia; 2011 Dec; 25(12):1891-9. PubMed ID: 21788946
[TBL] [Abstract][Full Text] [Related]
16. The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.
Pei XY; Dai Y; Rahmani M; Li W; Dent P; Grant S
Clin Cancer Res; 2005 Jun; 11(12):4589-600. PubMed ID: 15958645
[TBL] [Abstract][Full Text] [Related]
17. Sulphoraphane, a naturally occurring isothiocyanate induces apoptosis in breast cancer cells by targeting heat shock proteins.
Sarkar R; Mukherjee S; Biswas J; Roy M
Biochem Biophys Res Commun; 2012 Oct; 427(1):80-5. PubMed ID: 22975350
[TBL] [Abstract][Full Text] [Related]
18. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
19. Heat shock proteins in multiple myeloma.
Zhang L; Fok JH; Davies FE
Oncotarget; 2014 Mar; 5(5):1132-48. PubMed ID: 24675290
[TBL] [Abstract][Full Text] [Related]
20. Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.
Kim SH; Ahn KS; Jeong SJ; Kwon TR; Jung JH; Yun SM; Han I; Lee SG; Kim DK; Kang M; Chen CY; Lee JW; Kim SH
Eur J Pharmacol; 2011 Mar; 654(1):10-6. PubMed ID: 21172343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
